Cardiotonic drugs constitute a pharmaceutical class aimed at augmenting the contractile strength of the heart muscle and enhancing its pumping efficiency. This category of medications plays a pivotal role in addressing diverse cardiovascular conditions, particularly heart failure. Their mechanism involves bolstering the vigor of each cardiac contraction, ultimately improving cardiac output and ensuring efficient blood circulation throughout the body. Notable examples of cardiotonic drugs include milrinone and dobutamine, which work by influencing specific pathways to enhance myocardial contractility. The application of cardiotonic drugs is meticulously monitored due to their narrow therapeutic window and the potential for adverse effects. In contemporary medical practice, these medications are often integrated into comprehensive treatment plans, frequently alongside other cardiovascular drugs, to optimize therapeutic outcomes for individuals with various heart-related disorders.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation